C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-24

Study Completion Date

2024-12-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

NCT05420493

Relapsed Non-Hodgkin Lymphoma Refractory Non-Hodgkin Lymphoma Non Hodgkin Lymphoma

RECRUITING PHASE1

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

NCT06180174

B Cell Lymphoma Non Hodgkin Lymphoma

RECRUITING PHASE1

CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.

NCT04697290

B-cell Non-Hodgkin's Lymphoma

SUSPENDED EARLY_PHASE1

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

NCT04626739

Refractory Indolent Adult Non-Hodgkin Lymphoma

UNKNOWN EARLY_PHASE1

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

NCT05436223

B-cell Non-Hodgkin's Lymphoma

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma, B-Cell CAR-T

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

C752

Group Type EXPERIMENTAL

C752

Intervention Type BIOLOGICAL

C752 will be administered on Day 0

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

C752

C752 will be administered on Day 0

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent in accordance with federal, local, and institutional guidelines, Males and females ≥18 years of age at the time of consent
* Documented diagnosis of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
* Have progression by least one systemic treatment and no available standard of care treatment.
* At least one measurable lesion by Lugano 2014
* Expected survival ≥ 12 weeks
* Have an ECOG performance status of 0 or 1
* Adequate organ function
* Screening test indicates histopathological CD19 + if the subject received CD19-targeted therapy
* Women of childbearing age must have a negative pregnancy test, and agree to take effective contraception during the trial

Exclusion Criteria

* Treatment with any prior HSCT, gene therapy product, cell therapy product ect.
* Central nervous system involvement
* HBV/HCV
* HIV infection
* Concurrent use of systemic steroids or immunosuppression
* Uncontrolled active infection
* Wash-out period of from the last anti-cancer treatment
* Active second malignancy
* Have not recovered from the effects of previous therapy
* Have psychological or physical conditions that do not permit compliance with the protocol
* Pregnant or nursing (lactating) women

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No